Topics

Articles

It’s essential for commercial success, but presents its share of obstacles.

Beyond the Finish Line: Why Post-Approval Regulatory Strategy Matters

A pooled analysis of the SWIFT-1 and SWIFT-2 trials found 54% reduction in exacerbation rates over 52 weeks in patients with severe asthma with type 2 inflammation treated with depemokimab. 

GSK’s Depemokimab Significantly Reduces Asthma Exacerbations 

This year’s conference—taking place in Washington, DC— will prioritize the tackling of business, economic, and healthcare policy obstacles when it comes to decision marking and net revenue optimization. 

Pharma KOLs to Unite at Access Insights Conference 2024

ROCTAVIAN will only be sold to the United States, Italian, and German markets, as the company eyes its profitability by 2025. 

BioMarin Adjusts Sales Plan for Severe Hemophilia A Gene Therapy

The parties will continue to create new candidate therapies for the treatment of a severe form of TUBB4A leukodystrophy.

SynaptixBio, Evotec Extend Research and Development Collaboration

Expansion of these offerings will occur at the company’s 60,000 square-foot Lincolnshire Center of Excellence

SGS North America Strengthens Its Biologics Testing Services

Ashfield Event Experiences and WRG merge in an effort to better serve the healthcare industry. 

Introducing Emota: A New Inizio Engage Agency

Videos

In an interview with Pharma Commerce Editor Nicholas Saraceno, Lung-I Cheng, PhD, VP, Head of Cell & Gene Therapy Service Line, Cencora offers his thoughts on Cencora's inaugural ThinkLive Cell and Gene Therapy Summit.  

Cencora VP & Head of Cell & Gene Therapy Service Line Discusses the ThinkLive Cell and Gene Therapy Summit

Biosimilars market experiences massive growth, but regulatory and adoption challenges remain.

Getting the Lay of the Land After a Banner Year for Biosimilars

The CDMO’s multi-million-dollar expansion project features commercial manufacturing suites and peptide manufacturing plants.   

Commercial Channels